Contineum Therapeutics (CTNM) Cash & Equivalents (2023 - 2026)

Contineum Therapeutics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $14.7 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 29.22% year-over-year to $14.7 million; the TTM figure through Jun 2026 stood at $14.7 million (down 29.22% YoY), while the FY2025 annual figure was $75.6 million, up 244.54% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $14.7 million, down from $20.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $77.2 million in Q2 2024, with the low at $14.7 million in Q2 2026.
• The 4-year median for Cash & Equivalents is $21.9 million (2024), against an average of $33.5 million.
• Peak annual rise in Cash & Equivalents reached 244.54% in 2025, while the deepest fall reached 73.09% in 2025.
• Contineum Therapeutics' Cash & Equivalents stood at $15.5 million in 2023, then soared by 41.33% to $21.9 million in 2024, then surged by 244.54% to $75.6 million in 2025, then sank by 80.54% to $14.7 million in 2026.
• Business Quant data shows CTNM's Cash & Equivalents at $14.7 million in Q2 2026, $20.2 million in Q1 2026, and $75.6 million in Q4 2025.